A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: a phase I/II randomized, open-label, controlled trial

Table 4 Prognosis in 2 years after liver transplantation

	MSC (N = 11)	Rituximab (N = 11)	P value
Survival rate no. (%)	9 (81.8%)	8 (72.7%)	1.000
Graft survival rate no. (%)	9 (81.8%)	8 (72.7%)	1.000
Acute rejection no. (%)	1 (9.1%)	3 (27.3%)	0.586
Biliary complications no. (%)	0 (0%)	5 (45.5%)	0.035^a
Ischemia type biliary lesion no. (%)	0 (0%)	4 (36.4%)	0.090
Bile duct anastomotic stenosis no. (%)	0 (0%)	3 (27.3%)	0.214
Bile leakage no. (%)	0 (0%)	1 (9.1%)	1.000
Septic shock no. (%)	1 (9.1%)	9 (81.8%)	0.002^b
Pulmonary infection no. (%)	0 (0%)	8 (72.7%)	0.001^b
Biliary infection no. (%)	0 (0%)	1 (9.1%)	1.000
Splenic abscess no. (%)	1 (9.1%)	0 (0%)	1.000
Arteriostenosis no. (%)	1 (8.3%)	3 (27.3%)	0.586
De novo tumor no. (%)	0 (0%)	1 (9.1%)	1.000

ISSN: 1757-6512